Three conference posters lay out the biology behind lanifibranor, the French biotech's lead drug candidate. They explain the theory; they do not replace the Phase 3 trial results the company expects this quarter.
London-based OKYO Pharma has enrolled the first patients in a Phase 3 trial for a painful eye condition with no FDA-approved treatment. The start is real. The answer is still a trial away.
The gene editing company has booked a rheumatology meeting slot for early data on its donor-derived CAR T therapy in systemic sclerosis. The title refers to efficacy; the release discloses no data.
Turbo Energy's 15 firm orders in Spain and Chile average about 200,000 euros each on the company's figures. The release names no customer, gives no country split and does not say how much has already been recognized as revenue.
WISeKey International Holding Ltd (Nasdaq Global Market and SIX Swiss Exchange: WKEY) is redomiciling to the British Virgin Islands. The company says the move is about capital flexibility, not a change in operations.
Roche announced positive Phase III data for Tam-Peli in relapsed small-cell lung cancer, with the drug reducing death risk by 54% compared to standard treatment.
The Geneva biopharmaceutical company sold 437,869 ADSs under its ATM programme and said the proceeds extend its cash runway to the fourth quarter of 2027.
The St. Gallen sports technology group renewed its exclusive global rights to Euroleague Basketball official data and AV betting feeds, covering more than 650 games a year.
The Swiss online pharmacy group reported first-half external revenue of CHF 627.8 million and said it has increased all elements of its full-year 2026 guidance.
The Swiss plasma control and x-ray group reported a 5.6% rise in first-half net sales, a book-to-bill ratio of 1.48 and full-year sales guidance of CHF 540 to 570 million.
The Swiss anti-infectives specialist said BARDA released a further USD 30 million under an existing agreement after a prespecified enrollment milestone was met.
The Geneva cybersecurity and satellite group posted preliminary H1 2026 revenue up 115%, reported about $495 million in cash and reaffirmed full-year guidance.